Kidney Cancer Research Bureau
13
1
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
Role: lead
Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue
Role: lead
Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer
Role: lead
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
Role: lead
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
Role: lead
Testosterone in Metastatic Renal Cell Carcinoma Patients
Role: lead
Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO Therapy
Role: lead
Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
Role: lead
Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients
Role: lead
Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
Role: lead
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Role: lead
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
Role: lead
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
Role: lead
All 13 trials loaded